Select Page

Fixed Code

Jubak Picks Portfolio | Click to Expand Live Table

     Symbol      Company      Date Added Price
     Then
Target
     Price
Price
     Now
Today's
     Change
Jubak's
     Gain/Loss (%)
Nektar Therapeutics 47.00
Ctrip.com International Ltd 64.00
Arcos Dorados Holdings Inc. 15.00
SPDR Gold Shares 139.00
Danaher 99.00
Diamondback Energy, Inc. 130.00
ACADIA Pharmaceuticals Inc. 55.00
Autoliv, Inc. 134.00
Synaptics Incorporated 64.00
Alibaba Group Holding Limited 195.00
The Hain Celestial Group, Inc. 62.00
WisdomTree Japan Hedged Real Estate ETF 32.00
HDFC Bank Limited 62.00
Visa Inc. 117.00
Itau Unibanco Holding S.A. 18.00
Ionis Pharmaceuticals, Inc. 65.00
Incyte Corporation 142.00
Cheniere Energy, Inc. 62.00
Targa Resources Corp. 60.00
Xylem Inc. 63.00
Statoil ASA 24.00
MGM Resorts International 39.00
OncoGenex Pharmaceuticals, Inc. 22.00
Nektar Therapeutics (NKTR)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$47.00

Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say “Buy” in Jubak Picks even after this run

Nektar Therapeutics (NKTR) shares finished the day up 14.15% on fairly preliminary, but very important data from the trials of the company’s lead cancer drug. Those results go a long way to validating the company’s entire pipeline of drug candidates to treat cancer by boosting the body’s own immune system to fight tumors. (For more on that news see my earlier post on my subscription sites JubakAm.com and Juggling with Knives.) Perhaps over shadowed by that news, the company also reported significant movement on getting its new opioid, as effective as current opioids but much less addictive in trials to date, to the U.S. Food & Drug Administration, through the regulatory process on an expedited schedule, and to the market.

Posted in Breaking News, Buy, Jubak Picks Portfolio, NKTR, Volatility | Tagged , , , , , , | Leave a comment

Ctrip.com International Ltd (CTRP)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$64.00

I’m buying China’s online travel leader CTRP for my Jubak Picks portfolio today

There are three things to think about before buying Ctrip.com International (CTRP), the leader in China’s online travel market. Two of these things are positive and one negative. I think the balance comes down on the positive side but the negative element means the stock isn’t without risk.

Posted in Breaking News, Buy, CTRP, Jubak Picks Portfolio | Tagged , , , , , | Leave a comment

Arcos Dorados Holdings Inc. (ARCO)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$15.00

Buy Arco Dorados Holdings in my Jubak Picks portfolio

Arco Dorados Holdings (ARCO) is a twofer. The New York traded ADRs of the largest operator of McDonald’s (MCD) franchises in the world, is soaring on the recovery in its two biggest markets Brazil and Argentina.

Posted in ARCO, Breaking News, Buy, Jubak Picks Portfolio | Tagged , , , | Leave a comment

SPDR Gold Shares (GLD)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$139.00

Adding a gold ETF on today’s drop in the metal on hurricane, North Korea relief

I’m adding the SPDR Gold Shares ETF (GLD) to my Jubak Picks and Volatility portfolios today. Gold has sold off today with worries over a new missile test from North Korea in abeyance. And with traders relieved–and apparently surprised–to discover that Hurricane Irma didn’t wash Florida out to sea over the weekend. As I have noted over the last few days the likelihood is that the U.S. dollar will continue to weaken for the rest of 2017–if not longer.

Posted in Breaking News, Buy, GLD, Jubak Picks Portfolio, Volatility | Tagged , , , | 2 Comments

Danaher (DHR)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$99.00

Jubak Picks Danaher reports breakout quarter

On October 16 Jubak Picks Danaher (DHR) reported third quarter earnings of $1.00 a share, five cents a share above Wall Street expectations. Revenue grew by 9.7% year over year to $4.53 billion, above Wall Street projections of $4.47 billion. The company raised its guidance for the full 2017 year to earnings of $3.96 to $4.00 a share against the consensus estimate of $3.96 a share and above prior guidance of $3.90 to $3.97 a share. On the news the stock has decisively broken above its 50-day moving average

Posted in Breaking News, DHR, Jubak Picks Portfolio, Update | Tagged , , , | Leave a comment

Diamondback Energy, Inc. (FANG)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$130.00

My first picks for buying a piece of the Permian

What do you buy so that you’ve got a piece–and the best piece no less–of the Permian in your portfolio? You start, I think, with Pioneer Natural Resources. To me this producer is the standard for judging all other producers in the Permian. But I’ve found a second Permian picks that is, in some ways, better than Pioneer Natural Resources

Posted in Breaking News, Buy, FANG, Jubak Top 50 Portfolio | Tagged , , , , , | Leave a comment

ACADIA Pharmaceuticals Inc. (ACAD)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$55.00

Shares of Jubak Pick Acadia Pharmaceuticals pop 11% on buyout rumors

Update January 4. Shares of Acadia Pharmaceuticals (ACAD) were up 12% this morning, January 4, before closing with a gain of 11.02% to $31.94. The action came on rumors that Pfizer (PFE) or another big drug company would make a bid for the biotech on the strength of its lead drug Nuplazid

Posted in ACAD, Jubak Picks Portfolio, Update | Tagged , , | Leave a comment

Autoliv, Inc. (ALV)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$134.00

Autoliv earnings: So when is the future?

On October 26 Autoliv (ALV) reported third quarter earnings of $1.47 a share, 12 cents a share above the Wall Street consensus. Revenue climbed just 1.6% year over year to match the analyst projection at $2.5 billion. The problem in the quarter was revenue growth–or actually the lack thereof. Organic sales grew by just 0.5%, even lighter than guidance for 0% to 2% growth. And the company cut its forecast for full 2017 organic revenue growth to 1% from the prior 2% growth. The company made no bones about what it’s going through: “The third quarter turned out essentially as we had expected, Autoliv CEO Jan Carlson said. “We are in the midst of an intense period of preparing for our future growth, while delivering at the high end of our guided margin range for the quarter.”

Posted in ALV, Breaking News, Jubak Picks Portfolio | Tagged , , , , | Leave a comment

Synaptics Incorporated (SYNA)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$64.00

Synaptics reports earnings: So how’s that transition going?

Synaptics (SYNA) announced September quarter (first fiscal 2018 quarter) earnings after the market close on November 7. Earnings of $1.03 a share were 7 cents a share above the Wall Street consensus. Revenue climbed 8.1% year over year to $417 million against the $399 million Wall Street projection. The company issued guidance for the December quarter of $410 million to $450 million in revenue vs the Wall Street projection of $430 million. The stock was ahead a strong 8% in after hours trading on November 7 on the news.

Posted in Breaking News, Jubak Picks Portfolio, SYNA, Update | Tagged , , , , , | Leave a comment

Alibaba Group Holding Limited (BABA)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$195.00

Alibaba plans to use Singles’ Day shopping frenzy to lock in market dominance for years

Alibaba (BABA) generated $1 billion in gross merchandise volume in just the first three minutes of the Singles’ Day shopping event in China today. By the end of two hours the sales volume was just shy of $12 billion. The company’s Alibaba Cloud unit processed 325,000 orders per second at the peak during the first hour. But this huge volume of sales on a holiday, started as a celebration for China’s unattached, isn’t the big story for Alibaba today.

Posted in BABA, Breaking News, Jubak Picks Portfolio, Jubak Top 50 Portfolio | Tagged , , , , , | Leave a comment

The Hain Celestial Group, Inc. (HAIN)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$62.00

HAIN spikes 8.56% on news that an activist investor is pressing the company to sell itself

I’ve been waiting for this for more than a year. And so have a lot of other investors and traders from the market reaction today. Shares of Hain Celestial Group (HAIN) jumped 8.56% today on news that activist investor Engaged Capital had accumulated almost 10% of the company’s shares and was demanding that the company put itself up for sale. Engaged Capital has nominated seven candidates for the company’s board.

Posted in Breaking News, HAIN, Jubak Picks Portfolio, Update | Tagged , , , | Leave a comment

WisdomTree Japan Hedged Real Estate ETF (DXJR)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$32.00

Update Wisdom Tree Japan Hedged Real Estate ETF

Update: March 22, 2016. When I added Wisdom Tree Japan Hedged Real Estate ETF (DXJR) to my Jubak Picks portfolio back in December 2014, my idea was that investment flows from China into cheaper (and safer from government eyes) Tokyo real estate plus development for the 2020 Olympics would push prices in the Tokyo real […]

Posted in DXJR | 1 Comment

HDFC Bank Limited (HDB)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$62.00

Buy HDFC (HDB)

Only the third largest bank in India, but the best run under managing director Aditya Pura, the former CEO of Citibank Malaysia. Because HDFC’s base of retail deposits–from a network of 746 branches in 329 cities serving 10 million customers–provides about 40% of the capital it lends out, the bank has been able to maintain […]

Posted in Buy, HDB | Leave a comment

Visa Inc. (V)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$117.00

Visa beats on earnings and revenue as payment volumes climb by 9.8%

Today October 25 Visa (V) reported September quarter earnings of 90 cents a share, 5 cents a share above Wall Street projections. Revenue climbed 13.9% year over year to $4.86 billion vs. Wall Street projections of $4.63 billion. Payments volume, on a constant dollar basis, rose 10% year over year. Total processed transactions climbed 13% year over year.
 

Posted in Breaking News, Jubak Picks Portfolio, Update, V | Tagged , , , , | Leave a comment

Itau Unibanco Holding S.A. (ITUB)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$18.00

Itau Unibanco gains on interest rate cut but advance in Brazilian stocks is muted by arrest of another big-fish politico

Yesterday the Banco Central do Brasil reduced Brazil’s benchmark interest rate for the first time in four years. The cut, 25 basis points to 14%, was less than the 50 basis points the market was hoping for. But the dream is that it will be just the first of many reductions in the benchmark rate. The last time the Selic rate was reduced was in October 2012 when the bank cut to 7.25%. There’s obviously a lot of room for cuts here–if Brazil’s economy will cooperate. So why has the response been so relatively modest?

Posted in ITUB, Jubak Picks Portfolio, Update | Tagged , , , , , | Leave a comment

Ionis Pharmaceuticals, Inc. (IONS)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$65.00

Good news for Ionis pipeline from this trial–upping target price to $65

Sometimes the importance of a clinical trial extends way beyond the specific drug under study. That’s the case with the Phase II data recently released by Ionis for FIXRx. The trial did show efficacy in the treatment of kidney disease. But the most important results in the trial were what it didn’t show. There was no evidence that patients receiving the drug as part of the trial saw any reduction in platelet levels and no treatment-related bleeding events

Posted in IONS, Jubak Picks Portfolio, Update | Tagged , , , , , | 2 Comments

Incyte Corporation (INCY)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$142.00

Some signs the bottom is in for Incyte

This qualifies as a horrendous six months for any stock: Shares of Incyte (INCY) are down from $152.66 on March 15 to $115.19 at the close today, October 2. The shares have been even lower, which is one thing giving me some hope that the pain is coming to an end. The shares traded at $109.15 on September 26. What is frustrating about the plunge in this stock, a member of my Jubak Picks portfolio, is that it’s not based on a failure in the company’s drug pipeline or questions about its research program.

Posted in Breaking News, INCY, Jubak Picks Portfolio, Update | Tagged , , , , | Leave a comment

Cheniere Energy, Inc. (LNG)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$62.00

Cheniere Energy reports third quarter earnings below consensus but revenues show a strong beat–I’m raising my target price to $62

Yesterday Cheniere Energy (LNG) reported a loss for the third quarter of $1.24 a share, 74 cents a share worse that the Wall Street consensus. Revenue climbed 202% hear over year to $1.4 billion against Wall Street projections of $1.27 billion. The company also issued guidance for 2017 and 2018.

Posted in Breaking News, Jubak Picks Portfolio, LNG, Update | Tagged , , , | Leave a comment

Targa Resources Corp. (TRGP)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$60.00

Targa Resources can climb from here but the attraction is the 8% dividend

Last year prices for natural gas liquids fell even faster than oil prices did. Hard as that may be to believe. Which is why the price for shares of Targa Resources are down 23.16% for the last twelve months This year natural gas liquids have recovered faster than oil prices. Which is why the shares of this company, which runs a network of pipelines and storage facilities heavy on the transport of natural gas liquids, are up 62.66% for 2016 through September 2.

Posted in Breaking News, TRGP, Update | Tagged , , , | Leave a comment

Xylem Inc. (XYL)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$63.00

Xylem raises guidance for fiscal 2017 after slight earnings beat in second quarter

On August 1 Xylem (XYL) reported second quarter earnings of 59 cents a share (excluding one-time items), beating Wall Street earnings estimates by 2 cents a share. Thanks to recent acquisitions revenue of $1.16 billion climbed 24.9% year over year, slightly missing the analyst consensus of $1.17 billion. And the company raised guidance for 2017 to earnings of $2.30 to $2.40 a share

Posted in Breaking News, Jubak Picks Portfolio, Update, XYL | Tagged , , , , | Leave a comment

Statoil ASA (STO)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$24.00

Statoil’s second quarter: Better than the average oil company

Update: July 28, 2015. Statoil (STO) reported second quarter results today (July 28) that beat consensus estimates on both earnings (NOK3.15 a share vs. the NOK1.62 consensus) and revenue (NOK138.5 billion vs. NOK124.8 billion analyst consensus.) That doesn’t mean Statoil has found some way to magically sell oil for a higher price than competitors. Second […]

Posted in STO | Leave a comment

MGM Resorts International (MGM)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$39.00

Two typhoons don’t dent casino revenue growth in Macao

Casino revenue in Macao climbed by a year over year 20% in August, marking a 13th consecutive month of growth–despite two typhoons the left half of the city without power and water for as many as four days. Shares of MGM Resorts International (MGM), which is due to open a new casino on the Cotai Strip at the end of 2017, are up 10.84% from August 17 to 3 p.m. today, September 6.

Posted in Breaking News, Jubak Picks Portfolio, MGM | Tagged , , , | Leave a comment

OncoGenex Pharmaceuticals, Inc. (OGXI)
Symbol Date Added Buy Price Target Price Price Now Change Jubak's Gain/Loss (%)
$22.00

OncoGenex pops today on hopes for major cancer drug news tomorrow

Shares of biotech OncoGenex (OGXI) were up 8.9% today, March 10 at the close in New York. Why? Because March 10 is the day before March 11. The company is scheduled to report fourth quarter results on March 11 after the close of the New York market and speculation today is that the company will […]

Posted in OGXI | 5 Comments

Fixed Code

Cheniere Energy reports third quarter earnings below consensus but revenues show a strong beat–I’m raising my target price to $62

Yesterday Cheniere Energy (LNG) reported a loss for the third quarter of $1.24 a share, 74 cents a share worse that the Wall Street consensus. Revenue climbed 202% hear over year to $1.4 billion against Wall Street projections of $1.27 billion. The company also issued guidance for 2017 and 2018.

read more

Autoliv earnings: So when is the future?

On October 26 Autoliv (ALV) reported third quarter earnings of $1.47 a share, 12 cents a share above the Wall Street consensus. Revenue climbed just 1.6% year over year to match the analyst projection at $2.5 billion. The problem in the quarter was revenue growth–or actually the lack thereof. Organic sales grew by just 0.5%, even lighter than guidance for 0% to 2% growth. And the company cut its forecast for full 2017 organic revenue growth to 1% from the prior 2% growth. The company made no bones about what it’s going through: “The third quarter turned out essentially as we had expected, Autoliv CEO Jan Carlson said. “We are in the midst of an intense period of preparing for our future growth, while delivering at the high end of our guided margin range for the quarter.”

read more

Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say “Buy” in Jubak Picks even after this run

Nektar Therapeutics (NKTR) shares finished the day up 14.15% on fairly preliminary, but very important data from the trials of the company’s lead cancer drug. Those results go a long way to validating the company’s entire pipeline of drug candidates to treat cancer by boosting the body’s own immune system to fight tumors. (For more on that news see my earlier post on my subscription sites JubakAm.com and Juggling with Knives.) Perhaps over shadowed by that news, the company also reported significant movement on getting its new opioid, as effective as current opioids but much less addictive in trials to date, to the U.S. Food & Drug Administration, through the regulatory process on an expedited schedule, and to the market.

read more

Synaptics reports earnings: So how’s that transition going?

Synaptics (SYNA) announced September quarter (first fiscal 2018 quarter) earnings after the market close on November 7. Earnings of $1.03 a share were 7 cents a share above the Wall Street consensus. Revenue climbed 8.1% year over year to $417 million against the $399 million Wall Street projection. The company issued guidance for the December quarter of $410 million to $450 million in revenue vs the Wall Street projection of $430 million. The stock was ahead a strong 8% in after hours trading on November 7 on the news.

read more

Alibaba plans to use Singles’ Day shopping frenzy to lock in market dominance for years

Alibaba (BABA) generated $1 billion in gross merchandise volume in just the first three minutes of the Singles’ Day shopping event in China today. By the end of two hours the sales volume was just shy of $12 billion. The company’s Alibaba Cloud unit processed 325,000 orders per second at the peak during the first hour. But this huge volume of sales on a holiday, started as a celebration for China’s unattached, isn’t the big story for Alibaba today.

read more

Alibaba’s core business is going great; worries are at the investment margins

Yesterday before the market opened in New York China’s e-commerce giant Alibaba (BABA) reported September quarter earnings of $1.29 a share (excluding one-time items.) That was 26 cents a share better than Wall Street projections. Revenue climbed 61% to $8.63 billion for the quarter, again ahead of projections (at $7.86 billion.) I think it’s safe to conclude from the report that there is absolutely nothing wrong with the company’s core business in China

read more

Visa beats on earnings and revenue as payment volumes climb by 9.8%

Today October 25 Visa (V) reported September quarter earnings of 90 cents a share, 5 cents a share above Wall Street projections. Revenue climbed 13.9% year over year to $4.86 billion vs. Wall Street projections of $4.63 billion. Payments volume, on a constant dollar basis, rose 10% year over year. Total processed transactions climbed 13% year over year.
 

read more

Jubak Picks Danaher reports breakout quarter

On October 16 Jubak Picks Danaher (DHR) reported third quarter earnings of $1.00 a share, five cents a share above Wall Street expectations. Revenue grew by 9.7% year over year to $4.53 billion, above Wall Street projections of $4.47 billion. The company raised its guidance for the full 2017 year to earnings of $3.96 to $4.00 a share against the consensus estimate of $3.96 a share and above prior guidance of $3.90 to $3.97 a share. On the news the stock has decisively broken above its 50-day moving average

read more

Some signs the bottom is in for Incyte

This qualifies as a horrendous six months for any stock: Shares of Incyte (INCY) are down from $152.66 on March 15 to $115.19 at the close today, October 2. The shares have been even lower, which is one thing giving me some hope that the pain is coming to an end. The shares traded at $109.15 on September 26. What is frustrating about the plunge in this stock, a member of my Jubak Picks portfolio, is that it’s not based on a failure in the company’s drug pipeline or questions about its research program.

read more

Autoliv soars on news that the company might split its auto businesses in two

Shares of Autoliv (ALV) soared today, closing up 12.26% to $127.14, on news that the company’s Board of Directors has authorized management to conduct a strategic review of splitting the current company into two new companies focused on passive auto safety and auto electronics. Autoliv is a member of my Jubak Picks portfolio. Since adding it to the portfolio on April 29, 2016, the shares are up 3.82% as of today’s close. As of this post, I’m raising the current market price of $120 to $134. Splitting up the company would release value, the market believes, by separating the slower growing passive auto safety business from the very hot auto electronics operation

read more

Natural gas stocks up today on rise in LNG prices in Asia

Shares of natural gas producers and liquefied natural gas exporters climbed strongly today as prices for liquefied natural gas in Asia rose to s seven-month high in reaction to the damaged inflicted on Gulf Coast terminals by Hurricane Harvey. It didn’t hurt prices either that Chevron’s huge Gorgon liquefaction plant in Australia is shut and that other Australian plants expected to be in operation now face delays. Natural gas itself rose just 0.21% today to $3.07 per million BTUs. But shares of Chesapeake Energy (CHK), the second largest U.S. natural gas producer, and of Cheniere Energy (LNG), the first company to secure a completely unrestricted license to export liquefied natural gas, climbed 4.19% and 3.07% , respectively.

read more

Adding a gold ETF on today’s drop in the metal on hurricane, North Korea relief

I’m adding the SPDR Gold Shares ETF (GLD) to my Jubak Picks and Volatility portfolios today. Gold has sold off today with worries over a new missile test from North Korea in abeyance. And with traders relieved–and apparently surprised–to discover that Hurricane Irma didn’t wash Florida out to sea over the weekend. As I have noted over the last few days the likelihood is that the U.S. dollar will continue to weaken for the rest of 2017–if not longer.

read more

Nothing but good news for markets from European Central Bank today

At today’s meeting the European Central Bank announced that it would leave interest rates in negative territory and continue to buy debt assets at the current monthly rate. In his post-meeting press conference ECB president Mario Draghi noted that despite an increase in economic growth in the EuroZone to 2.3% year over year in the second quarter, the bank has yet to see a sustained increase in the rate of inflation that would lead to a change in policy.

read more

Two typhoons don’t dent casino revenue growth in Macao

Casino revenue in Macao climbed by a year over year 20% in August, marking a 13th consecutive month of growth–despite two typhoons the left half of the city without power and water for as many as four days. Shares of MGM Resorts International (MGM), which is due to open a new casino on the Cotai Strip at the end of 2017, are up 10.84% from August 17 to 3 p.m. today, September 6.

read more

Hurricane Harvey is demonstrating the new world of oil prices–and I’m selling refiner Marathon Petroleum into the storm

With Hurricane Harvey barreling down on the Gulf Coast complex of refineries and oil terminals, you might have expected the price of gasoline to rise yesterday, August 24, on fears of a shutdown of supply. And it did. The price of gasoline climbed 2.35% yesterday on the commodities market. The price of oil fell, though, with West Texas Intermediate falling 1.63% on the day.

read more

Xylem raises guidance for fiscal 2017 after slight earnings beat in second quarter

On August 1 Xylem (XYL) reported second quarter earnings of 59 cents a share (excluding one-time items), beating Wall Street earnings estimates by 2 cents a share. Thanks to recent acquisitions revenue of $1.16 billion climbed 24.9% year over year, slightly missing the analyst consensus of $1.17 billion. And the company raised guidance for 2017 to earnings of $2.30 to $2.40 a share

read more

One less worry hanging over shares of Jubak Pick Cheniere Energy

One worry hanging over shares of Cheniere Energy (LNG), the first company to get an unrestricted license to export liquified natural gas (LNG) to any country in the world, was what would happen if some of the customers that signed a long-term contract to buy LNG from Cheniere decide that they wanted to break its contract because of lower prices for natural gas. Well, now we have one example of exactly what happens–nothing. Which is good news for investors who own Cheniere.

read more

HAIN spikes 8.56% on news that an activist investor is pressing the company to sell itself

I’ve been waiting for this for more than a year. And so have a lot of other investors and traders from the market reaction today. Shares of Hain Celestial Group (HAIN) jumped 8.56% today on news that activist investor Engaged Capital had accumulated almost 10% of the company’s shares and was demanding that the company put itself up for sale. Engaged Capital has nominated seven candidates for the company’s board.

read more

Two big deals for Cheniere Energy

Cheniere Energy (LNG) has a significant first-mover advantage, I argued upon picking this stock for my Jubak Picks portfolio, since it was the first U.S. company to get a unrestricted permit to export liquified natural gas. Turning that advantage into revenue and earnings, however, always depended on Cheniere’s ability to move sales from the spot market to long term contracts. The company struck two more deals this past week.

read more

Adding water play Danaher to my Jubak Picks portfolio

In August 2015 Danaher acquired Pall for $13.8 billion. Then in 2016 Danaher spun off most of its industrial businesses into a new company called Fortiv. That left a refocused Danaher with four segments Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions. The former Pall business went into the Life Sciences segment. Through that segment Danaher is a provider of filtration, separation and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics and general industrial sectors. It’s this business that interests me as a water play in an age of capital rationing for supplies of clean water.

read more

Alibaba blows the top out on growth forecast; raising my target price

Yesterday, June 8, Alibaba (BABA) forecast that revenue would climb by 49% for fiscal 2018. That’s a solid 10 percentage points above the recent projection from Wall Street analysts. The New York traded ADRs climbed almost 10% on the news yesterday. They’re off 2.04% today against the background of a 1.80% drop in the NASDAQ Composite as a whole.

read more

Incyte up on positive trial results

Shares of Incyte (INCY) are up 7.1% as of 12:30 p.m. New York time on data released before the June meeting of the American Society of Clinical Oncology showing that Incyte’s epacadostat, which is an IDO inhibitor, has proved effective when used in combination with Merck’s (MRK) Keytruda and Bristol-Myers Squibb’s (BMY) Opdivo.

read more

Cheniere Energy pops on possibility of increased China exports

Earlier this week the Trump administration announced that it had reached an agreement with China to increase market access for U.S. energy companies. Today Cheniere Energy (LNG) noted that it has had extensive negotiations with Chinese state-owned companies about increasing shipments of liquefied natural gas (LNG) to China. Cheniere has sold nine cargoes of LNG on the spot market to China since it began exporting liquified natural gas in February 2016. The goal now for the company is moving from sales on the spot market to long-term contracts. On the news shares of Cheniere are up 3.24% as of 3:30 p.m. New York time.

read more

Sell Bristol-Myers Squibb before Thursday’s earnings report

I’m selling Bristol-Myers Squibb (BMY) out of my Jubak Picks portfolio ahead of Thursday’s report of first quarter earnings. I’m afraid that earnings will confirm what monthly sales reports from Bristol-Myers and competitors have outlined: That the company’s Opdivo cancer drug continues to lose market share among lung cancer treatments to drugs from Merck (MRK) and Roche Holding (RHHBY). That might not be a big deal–troubles with one drug, phfff–at another drug company or at another time, but Opdivo is critical to Bristol-Myers establishing the credibility of future growth with investors. Wall Street sees lung cancer as an estimated $10 billion to $15 billion market opportunity.

read more

Incyte dropped 10.5% yesterday on FDA drug “rejection”: Here’s what’s actually going on (and why you shouldn’t sell)

I know the headlines on Friday said that the U.S. Food and Drug Administration had “rejected” Olumiant (known more frequently until recently as baricitinib), a new drug for rheumatoid arthritis from Eli Lilly (LLY) and research lead Incyte Corp (INCY.) And on those headlines shares of Incyte dropped $14.77 a share on Monday to $126.07 from $140.84. The shares trickled lower to $125.84, down 0.13% today. What you need to know about this story is that the FDA didn’t reject baricitinib.

read more

Sell Vulcan Materials–I don’t see an infrastructure package this year

With the Senate about to go nuclear as Republicans change the Senate rules so they can avoid a Democratic filibuster and send Neil Gorsuch to the Supreme Court, any small chance that Democrats would work with Republicans to pass some version of President Trump’s $1 trillion infrastructure spending plan has gone from slim to none. Think Democrats will have any inclination to vote with Trump after seeing Republicans stonewall President Obama’s nominee for the court and then ram Gorsuch down their throats? And Trump needs Democratic votes because substantial numbers of the members of his own party in Congress will vote against infrastructure spending.

read more

Incyte is on the way to becoming a complete drug company–or an expensive acquisition candidate

Usually with a biotech stock you trade the present for the future: no revenue now but the promise of big revenue to come. Incyte’s (INCY) most recent quarter, reported on February 14, doesn’t require that trade off. Which means investors should be asking a different set of questions about the future of the company. For the quarter revenue climbed to $326.5 million, up 33.9% year over year.

read more

What’s the “quid” for Softbank’s “quo”?

Softbank (SFTBY) has been in the headlines a lot recently–usually after an announcement by President-elect Donald Trump. There was Softbank CEO and chairman Masayoshi Son emerging after a meeting with Trump at Trump Tower to announce that Softbank would invest $50 billion (of $100 billion raised in a new venture fund) in the United States and create 50,000 jobs in the U.S

read more

Raising my target price on Jubak Picks Cheniere Energy

The Cheniere Energy story is pretty simple. The company got the first license to export liquified natural gas from the United States, locked in long-term contracts for its Sabine Pass and Corpus Christi terminals, and then waited for revenue to flow in as the individual production trains at the two plants kicked in. What investors needed was patience–and sometimes strong nerves–as they contemplated the mountain of debt that Cheniere had used to fund its facilities and the fact that natural gas prices had tanked since the heady days when the company began to build its facilities. The third quarter of 2016, then marked something of a turning point for the company.

read more

Jim’s Daily Email Alerts:

Every post from Jubak Picks straight to your mailbox. And they're free!

Get Jim’s Special Offers:

Jim Jubak’s Special Offers
go out from time to time
(but never too often!)

Get Even More Jim!

  • • More profiles of hot (and cold) sectors
  • • More strategies for profiting from volatility
  • • More about macro trends driving the market
  • • More on where the market is heading – short-, medium- and long-term – including a Saturday Night Quarterback look at the week ahead!

Subscribe now for a year for just $199

Stock Trader's Almanac 2016 Best Investing Book